In a large series of 2404 @entity1 with a mean follow-up of 6.3 plus or minus 4.2 years (range, 1-17) after anatomic RRP for clinically localized @entity263 , 412 @entity1 (17%) have recurred. A detectable @entity11179 was the only evidence of recurrence in 9.7%, whereas 1.7% and 5.8% had local recurrence and distant @entity3 , respectively. The overall actuarial 5-, 10-, and 15-year recurrence-free survival rates for these @entity1 were 84%, 74%, and 66%, respectively. As demonstrated in the authors' previous reports, the actuarial likelihood of a postoperative recurrence increased with advancing clinical stage, Gleason-score, preoperative @entity11179 level, and pathologic stage. Subdivision of @entity1 with @entity5 resulted in better stratification. There was a similar actuarial likelihood of postoperative recurrence for @entity1 with Gleason 4 + 3 and Gleason score 8 to 10 disease. The actuarial rate of recurrence of @entity5 for @entity1 with Gleason 3 + 4 disease was statistically different from the rate for @entity1 with Gleason score 6 or Gleason 4 + 3 disease. The overall actuarial @entity3 -free survival rates at 5, 10, and 15 years were 96%, 90%, and 82%, respectively. The overall actuarial @entity5 -specific survival rates at 5, 10, and 15 years were 99%, 96%, and 90%, respectively. This study provides long-term outcome of @entity1 with clinically localized @entity5 who underwent RRP between 1982 and 1999. Recognizing that this long-term study includes many @entity1 with more advanced disease diagnosed before the @entity11179 era, caution must be exercised in comparing these results with the outcomes for cohorts of @entity1 treated since 1989. Anatomic RRP is an effective way to manage clinically localized @entity263 . Excellent long-term results can be obtained with RRP for early stage disease. The proportion of @entity1 with early @entity5 will continue to increase with wide use of serum @entity11179 testing and digital rectal examination.

Long-term biochemical disease-free and XXXX -specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience.

@entity1 :: ('9606', 'Species') :: ['patients', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'stage prostate cancer', 'Gleason 7 tumors', 'cancer'] @entity11179 :: ('9520', 'Gene') :: ['PSA'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity5 :: (MESH:D009369,Disease) :: ['cancer']
